Market Currents
Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals...
-
Thursday, September 6, 2012, 8:20 AM ETCelgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals in a Phase 3 study, and the biotech will now seek FDA and EU regulatory approval for the drug in 2013. Apremilast also achieved its primary goal in a separate study of patients with Behcet's disease, a rare inflammatory condition. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
